Related references
Note: Only part of the references are listed.Pathological role of a point mutation (T315I) in BCR-ABL1 proteinA computational insight
Vidya Rajendran et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling
Jianzhong Chen et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2017)
Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation
Peichen Pan et al.
ACS CENTRAL SCIENCE (2017)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Biophysical Aspect of Huntingtin Protein During polyQ: An In Silico Insight
Chandrasekhar Gopalakrishnan et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2016)
Mutational Analysis on Membrane Associated Transporter Protein (MATP) and Their Structural Consequences in Oculocutaeous Albinism Type 4 (OCA4)A Molecular Dynamics Approach
Balu Kamaraj et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening
Saemina Shin et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2016)
Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation
Jiao Jiao Li et al.
MOLECULAR BIOSYSTEMS (2016)
Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1
Vidya Rajendran
MOLECULAR BIOSYSTEMS (2016)
Impact of point mutation P29S in RAC1 on tumorigenesis
Vidya Rajendran et al.
TUMOR BIOLOGY (2016)
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
Joachim T. Siaw et al.
ONCOTARGET (2016)
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer
Sara Pilotto et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Novel ALK inhibitors in clinical use and development
Chaitanya Iragavarapu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Computational investigation of molecular mechanism and neuropathological implications in Huntington disease
Chandrasekhar Gopalakrishnan et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2015)
Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type I1/2 ALK inhibitors
Xiaotian Kong et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2015)
Structural analysis of membrane-bound hECE-1 dimer using molecular modeling techniques: insights into conformational changes and Aβ1-42 peptide binding
Kailas D. Sonawane et al.
AMINO ACIDS (2015)
ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
Federica Lovisa et al.
PLOS ONE (2015)
Drug resistance mechanism of PncA in Mycobacterium tuberculosis
Vidya Rajendran et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2014)
Role of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insight
Rituraj Purohit
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2014)
Exploring the structural and functional impact of the ALK F1174L mutation using bioinformatics approach
Anish Kumar et al.
JOURNAL OF MOLECULAR MODELING (2014)
The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice
Masamichi Mori et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches
Huiyong Sun et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Teeara Berry et al.
CANCER CELL (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Lung cancer in never smokers - A review
Sebastien Couraud et al.
EUROPEAN JOURNAL OF CANCER (2012)
Inhibitors of the anaplastic lymphoma kinase
Luca Mologni
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase
Linda F. Epstein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
Sen Zhang et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
Takaaki Sasaki et al.
CANCER RESEARCH (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Molecular pathogenesis of peripheral neuroblastic tumors
I. Janoueix-Lerosey et al.
ONCOGENE (2010)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Comparison of multiple amber force fields and development of improved protein backbone parameters
Viktor Hornak et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2006)
Development and testing of a general amber force field
JM Wang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Exploring protein native states and large-scale conformational changes with a modified generalized born model
A Onufriev et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2004)
The EGF receptor family as targets for cancer therapy
J Mendelsohn et al.
ONCOGENE (2000)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
